Balchem (BCPC) Stock Rating Lowered by BidaskClub

Balchem (NASDAQ:BCPC) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Thursday.

BCPC has been the topic of a number of other reports. ValuEngine cut Balchem from a “buy” rating to a “hold” rating in a research note on Thursday, November 1st. Pivotal Research upgraded Balchem from a “hold” rating to a “buy” rating and upped their price target for the stock from $95.00 to $100.00 in a research note on Tuesday. HC Wainwright set a $140.00 price target on Balchem and gave the stock a “buy” rating in a research note on Monday, October 15th. Finally, Sidoti upgraded Balchem from a “neutral” rating to a “buy” rating and set a $127.00 price target on the stock in a research note on Tuesday, October 16th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company’s stock. Balchem presently has a consensus rating of “Hold” and a consensus target price of $122.33.

NASDAQ:BCPC opened at $90.12 on Thursday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.82 and a current ratio of 3.42. Balchem has a 52 week low of $70.23 and a 52 week high of $117.79. The firm has a market cap of $2.91 billion, a price-to-earnings ratio of 30.75 and a beta of 0.97.

Balchem (NASDAQ:BCPC) last released its quarterly earnings results on Tuesday, November 6th. The basic materials company reported $0.73 EPS for the quarter, topping analysts’ consensus estimates of $0.61 by $0.12. Balchem had a return on equity of 14.51% and a net margin of 15.67%. The company had revenue of $155.04 million for the quarter, compared to analysts’ expectations of $163.66 million. During the same period in the prior year, the firm earned $0.63 earnings per share. The firm’s revenue was up 2.9% compared to the same quarter last year. As a group, analysts anticipate that Balchem will post 2.45 EPS for the current fiscal year.

Large investors have recently added to or reduced their stakes in the business. Oppenheimer Asset Management Inc. raised its stake in shares of Balchem by 9.8% in the second quarter. Oppenheimer Asset Management Inc. now owns 6,572 shares of the basic materials company’s stock valued at $646,000 after acquiring an additional 589 shares in the last quarter. Piedmont Investment Advisors LLC raised its stake in shares of Balchem by 9.3% in the second quarter. Piedmont Investment Advisors LLC now owns 7,482 shares of the basic materials company’s stock valued at $734,000 after acquiring an additional 635 shares in the last quarter. Amalgamated Bank raised its stake in shares of Balchem by 14.7% in the second quarter. Amalgamated Bank now owns 5,224 shares of the basic materials company’s stock valued at $513,000 after acquiring an additional 671 shares in the last quarter. Victory Capital Management Inc. raised its stake in shares of Balchem by 15.9% in the second quarter. Victory Capital Management Inc. now owns 6,316 shares of the basic materials company’s stock valued at $620,000 after acquiring an additional 865 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in shares of Balchem by 13.2% in the third quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 7,690 shares of the basic materials company’s stock valued at $862,000 after acquiring an additional 898 shares in the last quarter. Institutional investors own 88.48% of the company’s stock.

About Balchem

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, medical sterilization, and industrial markets in the United States and internationally. The company's Human Nutrition & Health segment supplies ingredients in the food and beverage industry.

Further Reading: Compound Interest and Why It Matters When Investing

Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply